cached image

David J. Waxman, Ph.D.

1983-1993 Dana-Farber Cancer Institute Harvard Medical School, Boston, MA, United States 
 1994- Biology Boston University School of Medicine, Boston, MA 
"David Waxman"
Mean distance: 7.27


Sign in to add mentor
Jack L. Strominger grad student 1980 Harvard
 (Structural studies of penicillin-sensitive D-alanine carboxypeptidase)
Christopher T. Walsh post-doc 1982-1983 MIT
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Haery L, Mussakhan S, Waxman DJ, et al. (2016) Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. Leukemia & Lymphoma. 1-11
Oshida K, Vasani N, Waxman DJ, et al. (2016) Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event. Plos One. 11: e0148308
Jordan M, Waxman DJ. (2015) CpG-1826 immunotherapy potentiates anti-tumor and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Letters
Melia T, Hao P, Yilmaz F, et al. (2015) Hepatic lincRNAs: high promoter conservation and dynamic, sex-dependent transcriptional regulation by growth hormone. Molecular and Cellular Biology
Wu J, Waxman DJ. (2015) Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory. Oncoimmunology. 4: e1005521
Suvorov A, Waxman DJ. (2015) Early programing of uterine tissue by bisphenol A: Critical evaluation of evidence from animal exposure studies. Reproductive Toxicology (Elmsford, N.Y.)
Doloff JC, Waxman DJ. (2015) Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. Bmc Cancer. 15: 375
Wu J, Waxman DJ. (2014) Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Letters. 353: 272-80
Doloff JC, Chen CS, Waxman DJ. (2014) Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Molecular Cancer. 13: 158
Chen CS, Doloff JC, Waxman DJ. (2014) Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia (New York, N.Y.). 16: 84-96
See more...